Literature DB >> 5485142

The effect of amiodarone, a new anti-anginal drug, on cardiac muscle.

B N Singh, E M Vaughan Williams.   

Abstract

1. Amiodarone (2-butyl, 3-(4-diethylaminoethoxy, 3,5-diiodo, benzoyl) benzofuran hydrochloride), an anti-anginal drug which causes coronary dilatation and depresses myocardial oxygen consumption, was found to protect anaesthetized guinea-pigs against ouabain-induced ventricular fibrillation.2. A 5% (73.4 mM) solution of amiodarone had no local anaesthetic action on guinea-pig skin.3. Amiodarone, 20 mg/kg (29.4 mumol/kg) given daily for 6 weeks intraperitoneally, had no effect on the resting potential or action potential height, and only a small effect on the maximum rate of depolarization, of isolated rabbit atrial or ventricular muscle fibres as shown by intracellular recording. It caused a considerable prolongation of the action potential in both tissues.4. Simultaneous administration of thyroxine (5 mug; 6.26 nmol), given daily for 3 weeks intraperitoneally, prevented the prolongation by amiodarone of the duration of the action potential.5. Treatment of rabbits with 20 mg/kg of amiodarone daily intraperitoneally for 6 weeks had no effect on the weight of the thyroid gland, but was associated with a reduction in body growth rate.6. Treatment of rabbits with 10 mg/kg (60.3 mumol/kg) of potassium iodide (equal in its iodine content to that of 20 mg/kg of amiodarone), given daily for 6 weeks intraperitoneally, had no effect on body growth rate or the duration of cardiac action potentials.7. It was concluded that amiodarone had effects on cardiac action potentials similar to those which occur after thyroidectomy.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5485142      PMCID: PMC1702721          DOI: 10.1111/j.1476-5381.1970.tb09891.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  18 in total

1.  The distribution and metabolism of thyroxine and 3:5:3'-triiodothyronine in the rabbit.

Authors:  K Brown-Grant; J R Tata
Journal:  J Physiol       Date:  1961-06       Impact factor: 5.182

2.  [Research on the benzofuran series. XL. Anti-arrhythmic properties of amiodarone].

Authors:  R Charlier; G Delaunois; J Bauthier; G Deltour
Journal:  Cardiologia       Date:  1969

3.  [On a new drug for the management of angina pectoris, Amiodarion].

Authors:  E F Hueber; R Kotzaurek
Journal:  Wien Med Wochenschr       Date:  1968-07-27

4.  [A clinical study of amiodarone].

Authors:  A Jouve; J L Medvedowsky; R Benyamine
Journal:  Ann Cardiol Angeiol (Paris)       Date:  1969 Jan-Mar

5.  Some biochemical effects of amiodarone.

Authors:  J Broeckhuysen; G Deltour; M Ghislain
Journal:  Arzneimittelforschung       Date:  1969-11

6.  [Clinical trial of amiodarone in coronary disorders].

Authors:  J Barzin; A Fréson
Journal:  Brux Med       Date:  1969-02

7.  The effect of some catecholamine beta-receptor blocking compounds on the toxicity to the heart of ouabain.

Authors:  J G Papp; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1969-05       Impact factor: 8.739

8.  Pharmacology of amiodarone, and anti-anginal drug with a new biological profile.

Authors:  R Charlier; G Deltour; A Baudine; F Chaillet
Journal:  Arzneimittelforschung       Date:  1968-11

9.  The effect of bretylium on intracellular cardiac action potentials in relation to its anti-arrhythmic and local anaesthetic activity.

Authors:  J G Papp; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1969-10       Impact factor: 8.739

10.  The relevance of beta-receptor blockade to ouabain-induced cardiac arrhythmias.

Authors:  A N Dohadwalla; A S Freedberg; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1969-06       Impact factor: 8.739

View more
  115 in total

1.  Investigations to characterize a new anti-arrhythmic drug, ORG 6001 including a simple test for calcium antagonism.

Authors:  L A Salako; V Williams; J H Wittig
Journal:  Br J Pharmacol       Date:  1976-06       Impact factor: 8.739

Review 2.  Mechanisms of antiarrhythmic drug actions and their clinical relevance for controlling disorders of cardiac rhythm.

Authors:  Uma Srivatsa; Nitin Wadhani; Bramah N Singh
Journal:  Curr Cardiol Rep       Date:  2002-09       Impact factor: 2.931

3.  Block of cardiac sodium channels by amiodarone studied by using Vmax of action potential in single ventricular myocytes.

Authors:  H Honjo; I Kodama; K Kamiya; J Toyama
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

Review 4.  A prolonged QTc interval. Is it an important effect of antiarrhythmic drugs?

Authors:  F A Fish; D M Roden
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Nov-Dec

Review 5.  Best practice in primary care pathology: review 4.

Authors:  W S A Smellie; J Forth; S Sundar; E Kalu; C A M McNulty; E Sherriff; I D Watson; C Croucher; T M Reynolds; P J Carey
Journal:  J Clin Pathol       Date:  2006-05-19       Impact factor: 3.411

Review 6.  Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance.

Authors:  S Nattel
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

Review 7.  Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.

Authors:  Ahmed M A Adlan; Gregory Y H Lip
Journal:  Drug Saf       Date:  2013-02       Impact factor: 5.606

8.  Evaluation of antagonism of aconitine-induced dysrhythmias in mice as a method of detecting and assessing antidysrhythmic activity.

Authors:  E Winslow
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

9.  Amiodarone prophylaxis for tachycardias after coronary artery surgery: a randomised, double blind, placebo controlled trial.

Authors:  J Butler; D R Harriss; M Sinclair; S Westaby
Journal:  Br Heart J       Date:  1993-07

Review 10.  Clinical pharmacokinetics of amiodarone.

Authors:  R Latini; G Tognoni; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.